Guidelines for good practice of intravesical instillations of BCG and mitomycin C from the French national cancer committee (CC-AFU) for non-muscle invasive bladder cancer;Recommandations du comité de cancérologie de l'Association française d'urologie (CC-AFU) pour la bonne pratique des instillations endovésicales de BCG et de mytomycine C dans le traitement des tumeurs de la vessie n'envahissant pas le muscle (TVNIM)

Progres en Urologie

Volumn 22, Issue 15, 2012, Pages 920-931

  Roupret M ^a   Neuzillet, Y ^b   Larre S ^c   Pignot, G ^d   Coloby, P ^e   Rebillard X ^f   Mongiat Artus, P ^g   Chartier Kastler, E ^a   Soulie M ^h   Pfister, C ⁱ  

^a SORBONNE UNIVERSITÉ   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c ANGERS UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e Service d'urologie   (France)

^f Clinique Beau Soleil   (France)

^g SAINT LOUIS HOSPITAL   (France)

^h UNIVERSITÉ DE TOULOUSE   (France)

ⁱ UNIVERSITÉ DE ROUEN   (France)

Author keywords

Bladder; Bladder instillation; Complications; Mitomycin; Mycobacterium bovis; NMIBC; Prognosis; Recurrence; Survival; Urothelial carcinoma

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; BCG VACCINE; IMMUNOLOGICAL ADJUVANT; MITOMYCIN;

BLADDER TUMOR; CANCER INVASION; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; PATHOLOGY; PRACTICE GUIDELINE; SHORT SURVEY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; ANTIBIOTICS, ANTINEOPLASTIC; BCG VACCINE; HUMANS; MITOMYCIN; NEOPLASM INVASIVENESS; URINARY BLADDER NEOPLASMS;

EID: 84867991819     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.purol.2012.05.002     Document Type: Short Survey

References (30)

1. Ploeg M., Aben K.K., Kiemeney L.A. The present and future burden of urinary bladder cancer in the world. World J Urol 2009, 27:289-293.
2. Pfister C., Roupret M., Wallerand H., et al. Recommandations en onco-urologie 2010 : tumeurs urothéliales. Prog Urol 2010, 20:S255-S274.
3. Babjuk M., Oosterlinck W., Sylvester R., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011, 59:997-1008.
4. Descazeaud A., Mignard J.P., Davin J.L., Irani J. Traitement par instillations vésicales de BCG et mitomycine C dans les tumeurs de vessie n'infiltrant pas le muscle : enquête de pratique de l'AFU auprès des urologues francais. Prog Urol 2009, 19:624-631.
5. Chopin D., Saint F., Gattegno B. Immunothérapie endovésicale : le bacille de Calmette-Guerin. Prog Urol 2001, 11:1067-1115.
6. Chamie K., Saigal C.S., Lai J., et al. Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer 2011, 117:5392-5401.
7. Neuzillet Y., Roupret M., Wallerand H., et al. Diagnostic et prise en charge des évènements indésirables survenant au décours des instillations endovésicales de BCG pour le traitement des tumeurs de vessie n'infiltrant pas le muscle (TVNIM) : revue du comité de cancérologie de l'Association française d'urologie. Prog Urol 2012, 22.
8. Sylvester R.J., van der M.A., Lamm D.L. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002, 168:1964-1970.
9. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006, 49:466-475. [discussion 475-77].
10. Oosterlinck W., Sylvester R., Babjuk M., et al. Should all patients receive an immediate chemotherapeutic drug instillation after resection of papillary bladder tumors?. Eur Urol 2011, 59:374-376.
11. Brausi M., Witjes J.A., Lamm D., et al. A review of current guidelines and best practice recommendations for the management of non-muscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 2011, 186:2158-2167.
12. Witjes F., Palou J., Soloway M., et al. Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events. Eur Urol Suppl 2008, 667.
13. Gontero P., Bohle A., Malmstrom P.U., et al. The role of bacillus Calmette-Guerin in the treatment of non-muscle-invasive bladder cancer. Eur Urol 2010, 57:410-429.
14. Herr H.W., Dalbagni G., Donat S.M. Bacillus Calmette-Guerin without maintenance therapy for high-risk non-muscle-invasive bladder cancer. Eur Urol 2011, 60:32-36.
15. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000, 163:1124-1129.
16. Neuzillet Y., Lebret T. Les vraies contre-indications du BCG dans le traitement des tumeurs de vessie. Prog Urol 2010, 20:S41-S45.
17. Van Outryve S.M., Francque S.M., Gentens P.A., et al. Bacillus Calmette-Guerin-induced granulomatous hepatitis in a patient with a superficial bladder carcinoma. Eur J Gastroenterol Hepatol 2004, 16:1027-1032.
18. Pisters L.L., Tykochinsky G., Wajsman Z. Intravesical bacillus Calmette-Guerin or mitomycin C in the treatment of carcinoma in situ of the bladder following prior pelvic radiation therapy. J Urol 1991, 146:1514-1517.
19. Falkensammer C., Gozzi C., Hager M., et al. Late occurrence of bilateral tuberculous-like epididymo-orchitis after intravesical bacille Calmette-Guerin therapy for superficial bladder carcinoma. Urology 2005, 65:175.
20. Lamm D.L., Steg A., Boccon-Gibod L., et al. Complications of Bacillus Calmette-Guerin immunotherapy: review of 2602 patients and comparison of chemotherapy complications. Prog Clin Biol Res 1989, 310:335-355.
21. Leibovici D., Zisman A., Chen-Levyi Z., et al. Elevated prostate specific antigen serum levels after intravesical instillation of bacillus Calmette-Guerin. J Urol 2000, 164:1546-1549.
22. Tinazzi E., Ficarra V., Simeoni S., Peterlana D., Lunardi C. Reactive arthritis following BCG immunotherapy for bladder carcinoma. Clin Rheumatol 2005, 24:425-427.
23. Saint F., Irani J., Patard J.J., et al. Tolerability of bacille Calmette-Guerin maintenance therapy for superficial bladder cancer. Urology 2001, 57:883-888.
24. Catto J.W. Thirty-five years of intravesical bacillus Calmette-Guerin for bladder cancer: where now?. Eur Urol 2011, 60:37-38.
25. Yates D.R., Roupret M. Contemporary management of patients with high-risk non-muscle-invasive bladder cancer who fail intravesical BCG therapy. World J Urol 2011, 29:415-422.
26. Shelley M.D., Wilt T.J., Court J., et al. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004, 93:485-490.
27. Colombel M., Saint F., Chopin D., et al. The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 2006, 176:935-939.
28. Ritz N., Tebruegge M., Connell T.G., et al. Susceptibility of Mycobacterium bovis BCG vaccine strains to antituberculous antibiotics. Antimicrob Agents Chemother 2009, 53:316-318.
29. Zuiverloon T.C., Nieuweboer A.J., Vekony H., et al. Markers predicting response to bacillus Calmette-Guerin immunotherapy in high-risk bladder cancer patients: a systematic review. Eur Urol 2012, 61:128-145.
30. Andius P., Fehrling M., Holmang S. Intravesical bacillus Calmette-Guerin therapy: experience with a reduced dwell-time in patients with pronounced side-effects. BJU Int 2005, 96:1290-1293.